NCT01942083: A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) |
|
|
| Terminated | 1 | 33 | RoW | OPB-111077 | Korea Otsuka Pharmaceutical Co., Ltd. | Advanced Hepatocellular Carcinoma | 06/16 | 07/16 | | |
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy |
|
|
| Completed | 1 | 37 | US | STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis | Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical | Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 01/24 | 03/24 | | |
